Ulcerative Colitis: Update Bulletin [Feb 2016]
Gain new KOL insights on the latest events happening in Ulcerative Colitis. Topics covered include opinions regarding Phase III data on Johnson & Johnson’s Stelara (ustekinumab) in Crohn’s disease and the launch of a new study looking at use of the therapy in patients with UC; the recent filing in the US and EU for Amgen’s ABP 501 (a proposed adalimumab biosimilar); the FDA advisory committee’s decision to recommend approval of Celltrion’s CT-P13 (a proposed infliximab biosimilar); as well as opinions on the early development of both Qu Biologics’ QBECO and Protagonist Therapeutics’ PTG 100.
Key Questions Answered in this Update Bulletin:
- How do KOLs perceive Stelara’s potential in the UC market?
- How do KOLs perceive the potential of ABP 501 (a Humira biosimilar) in the UC marketplace?
- What impact do they believe the arrival of biosimilar Humira will have on the market?
- What do KOLs think of the so-called ‘switching trials,’ which see patients transitioned from an originator therapy to a biosimilar?
- Do such trials boost confidence in prescribing biosimilars in UC?
- What are KOLs’ opinions of an FDA committee’s decision to recommend approval of CT-P13, a biosimilar version of Janssen’s Remicade?
- What do KOLs think of the mechanism of action behind QBECO?
- Where in the treatment paradigm might QBECO be placed if approved?
- How clinically attractive is Protagonist Therapeutics’ PTG 100?
Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.
Please Note: Due to the brevity and/or nature of the content posted, there is no table of contents available for this report.